about
DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteriesCrucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ERThree mutations in sterol-sensing domain of SCAP block interaction with insig and render SREBP cleavage insensitive to sterols.Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesisIncretin-based drugs for type 2 diabetes: Focus on East Asian perspectivesMolecular cloning, characterization, and chromosomal localization of FKBP23, a novel FK506-binding protein with Ca2+-binding abilityGlucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetenerComparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes.Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrationsPredicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levelsDipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic control.Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in JapaneseGlucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.GIP and GLP-1, the two incretin hormones: Similarities and differencesLittle enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls.Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea.Relationship and factors responsible for regulating fasting and post-challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SUse of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East AsiansActivation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice.Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signaling.Smoking and adipose tissue inflammation suppress leptin expression in Japanese obese males: potential mechanism of resistance to weight loss among Japanese obese smokersInsulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance.Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocinFibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidaseTwo incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.Incretin actions beyond the pancreas: lessons from knockout mice.Alogliptin benzoate for the treatment of type 2 diabetes.Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 - the gut, the islets or both?Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.Circadian rhythms and diabetes.Cardiovascular safety trials of incretin-based drugs: What do they mean?Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFGlucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points.
P50
Q22010449-B982AF08-C1E5-439C-B64C-D2F5A7DDFA51Q24305459-7E2E0FC7-21D0-4541-9BF5-7EF6C4A6E32FQ24543928-6D4FE878-785A-4FFD-A530-9A01C3F305B0Q24554492-A4AF2506-48BE-4D9C-AF7F-8739AA73BC88Q26749165-8CDCCF49-1A1F-4458-BABE-91A8AAD8CD3BQ28585202-F2664119-3418-45FD-9043-F273CA28AE0EQ28660291-EC3F1D3B-6134-41C9-AB09-62D85DC44118Q33585686-2E74F8BE-5525-4244-B773-5AEB47B1BB53Q33587800-875AFB62-4707-40E4-B18A-D78A6852421FQ33603319-FB311EDB-6B20-4F6B-B7BF-0939958EE256Q33603342-8C58530F-C879-4DCD-A3B5-21A126B107E7Q33603357-DCDD794B-D042-4E1F-8BF8-E394C6BB55CEQ33603384-9386CD00-8C56-408C-BFAF-ADFC2139E7B2Q33607749-64A8A2D5-BBB8-43E5-A1D2-E41D645E88F0Q33609502-FBE7318E-CF8C-4BE3-B6EF-42960E946AA5Q33609513-79163AA9-3114-44AA-8BAC-A0CEBCD75F14Q33626249-77327249-BA6B-4BF6-B36D-1FDE638CAA3BQ34299579-4E78A86E-D6C0-4375-B881-B652727548D7Q34407909-6BD510EF-0997-44CC-A615-1626F7C9C049Q34523674-3D48F24D-9C13-4184-9798-35650D57C38EQ35192193-A5847DC2-690A-409B-923C-00DCE631F7F8Q35538305-24BB7CB5-2555-4652-8E6C-DEBBF50CF46CQ35572729-04BCEE34-2013-48C3-8558-FC432AC5E536Q35616311-EA77968C-7D54-4B12-B075-62A4F99F3DC3Q35616437-412891FF-1546-4367-8CD6-957331E07DCFQ36000446-83C66394-52EC-481E-B405-190C41F722CAQ36409060-A73E41B3-CEAC-4C50-B0B0-C506EB05577AQ36547683-E1DDB2CA-8F2F-4EE8-AE01-2D95387A785BQ36990110-79DC534B-9038-4EA0-B8AF-F1964E0C2765Q37419190-FC4A02E7-FE76-4681-9617-BAE5D35EFA71Q37912391-821C3FAB-D2DF-4B4C-A2FD-6F5561A63363Q38149622-9C3EB8FB-77AE-45B9-8A94-5991EF3ED257Q38197275-7386C7FE-19AB-4435-A574-DA1F719A7AF4Q38647717-22532FE2-FEAC-45D5-BF03-25D8EAE5F0EEQ38659960-0875579C-EDC4-4848-B755-2192B7CF2B85Q38662950-922EF8CC-F3C6-4BEB-9B74-57C4F98A3F56Q39402832-CE24A55C-855C-4650-97BB-A34F1686917EQ39406260-2384E4C1-55F3-4298-9A1F-B42F4ACBC2D5Q39597921-C1C53EC4-9B87-4DA5-9C89-2C297ACC1056Q41008682-BE679D6A-8E2E-4C14-B757-FE630F7A41E2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daisuke Yabe
@ast
Daisuke Yabe
@en
Daisuke Yabe
@es
Daisuke Yabe
@nl
Daisuke Yabe
@sl
type
label
Daisuke Yabe
@ast
Daisuke Yabe
@en
Daisuke Yabe
@es
Daisuke Yabe
@nl
Daisuke Yabe
@sl
altLabel
Dai Yabe
@en
prefLabel
Daisuke Yabe
@ast
Daisuke Yabe
@en
Daisuke Yabe
@es
Daisuke Yabe
@nl
Daisuke Yabe
@sl
P108
P1053
J-6682-2014
P106
P1153
6602972745
P2038
Daisuke_Yabe2
P21
P31
P3829
P496
0000-0002-5334-7687
P569
2000-01-01T00:00:00Z